- Hillrom Holdings Inc HRC Q3 adjusted EPS of $1.38 beat the consensus of $1.34, exceeded the Company's previously issued guidance range of $1.32 to $1.36.
- Q3 results reflect a difficult comparison to Q3 2020, which benefited from a surge in one-time COVID-related revenue of approximately $130 million and adjusted EPS of $0.60.
- Revenue decreased 6% Y/Y to $718 million on a reported basis and 9% on a constant currency (CC) basis. Excluding last year's one-time COVID-related revenue of Med-Surg and ICU bed systems and non-invasive ventilators, revenues are up 13% on a reported basis and 10% on a constant currency basis.
- Patient Support Systems revenue of $376 million declined 16% (18% CC); excluding COVID-related revenue, the segment witnessed an 11% jump in sales (9% CC), reflecting normalized demand for bed systems & rentals.
- Front Line Care's revenue of $266 million increased 6% (3% CC), the revenue increased 17% (14% CC) without ventilator orders as physician office visits return to pre-COVID levels.
- Surgical Solutions' revenue was up 12% (8% CC) to $76 million, driven by an upturn in demand for operating room tables and patient positioning products as surgical procedures rebound.
- Outlook: For FY21, Hillrom raised revenue outlook to increase 3% - 4%, with adjusted EPS of $6.08 to $6.12 (consensus $6.06), compared to previous guidance of 1% - 3% growth and adjusted earnings of $6.00 - $6.10.
- It expects Q4 sales to increase by 6% - 7% and adjusted EPS of $1.44 to $1.48.
- Recently, Hillrom stock gained on reports of Baxter in initial talks to acquire the Company.
- Price Action: HRC shares closed at $136.86 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
